Trial Profile
A Randomised, Double-blind, Parallel Group, Multicentre, Stratified, Study Evaluating the Efficacy and Safety of Once Daily Fluticasone Furoate/Vilanterol Inhalation Powder Compared to Once Daily Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Participants Aged 5 to 17 Years Old (Inclusive) Currently Uncontrolled on Inhaled Corticosteroids
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary) ; Fluticasone furoate; Salbutamol
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 24 May 2023 Results assessing efficacy and safety of once-daily (QD) fluticasone furoate (FF)/vilanterol (VI) versus FF in children and adolescents with uncontrolled mild asthma on ICS monotherapy presented at the 119th International Conference of the American Thoracic Society
- 01 Dec 2022 This trial has been completed in Poland,according to European Clinical Trials Database record (21 Mar 2022).
- 29 Apr 2022 Status changed from recruiting to completed.